膀胱尿路上皮癌中PD-L1和PD-L2的表达及临床意义  

Expression of PD-L1 and PD-L2 in urothelial bladder cancer and their clinicopathological significance

作　　者：吴雅珣 张邢松 郑桂华[1] WU Ya-xun;ZHANG Xing-song;ZHENG Gui-hua(Department of Pathology,Nantong Cancer Hospital,Nantong 226361,China)

机构地区：[1]江苏省南通市肿瘤医院病理科,南通226361

出　　处：《临床与实验病理学杂志》2021年第2期151-156,共6页Chinese Journal of Clinical and Experimental Pathology

基　　金：江苏省南通市科技项目(MS12019017)。

摘　　要：目的探讨膀胱尿路上皮癌(urothelial bladder cancer, UBC)中程序性死亡配体-1(programmed death-ligand 1, PD-L1)以及程序性死亡配体-2(programmed death-ligand 2, PD-L2)的表达及临床意义。方法采用免疫组化法检测58例UBC组织中PD-L1、PD-L2的表达,分析两者表达与UBC临床病理特征的关系。结果肿瘤细胞PD-L1在高级别UBC、pT2-pT4 UBC中的表达高于低级别UBC、pTa-pT1 UBC(cut-off值为1%、10%、50%,P均<0.05)。cut-off值为5%时,肿瘤浸润性免疫细胞(tumor-infiltrating immune cell, TIIC)PD-L1在高级别UBC、pT2-pT4 UBC中的表达高于低级别UBC、pTa-pT1 UBC(P均<0.05);cut-off值为10%时,TIIC PD-L1在pT2-pT4 UBC中的表达高于pTa-pT1 UBC(P=0.014)。肿瘤细胞PD-L2表达与UBC组织学分级以及pT分期等临床病理参数均无关(P均>0.05)。cut-off值为50%时,TIIC PD-L2在pT2-pT4 UBC中的表达高于pTa-pT1 UBC(P=0.044)。肿瘤细胞PD-L1、PD-L2表达状态与UBC患者的总生存期(overall survival, OS)均无关(P均>0.05)。cut-off值为5%时,TIIC PD-L1高表达患者比低表达患者的OS缩短(P=0.011);TIIC PD-L2表达状态与患者的OS无相关性(P均>0.05)。结论 UBC肿瘤细胞及TIIC异常表达PD-L1及PD-L2,评估UBC中PD-L1、PD-L2的表达状态可为临床开展免疫治疗提供参考。Purpose To investigate the expression and clinicopathological significance of programmed death-ligand 1(PD-L1)and programmed death-ligand 2(PD-L2)in urothelial bladder cancer(UBC).Methods Immunohistochemistry was used to determine the expression levels of PD-L1 and PD-L2 in tissue microarrays containing 58 cases of UBC.The relationships between the expression levels of PD-L1 and PD-L2 and clinicopathological features of UBC were also analyzed.Results The expression levels of PD-L1 on tumor cells(TC)in high-grade UBC and pT2-pT4 tumors were higher than that in low-grade UBC and pTa-pT1 tumors(all P<0.05 at cut-off points of 1%,10%and 50%).At a cut-off of 5%,the expression levels of PD-L1 on tumor-infiltrating immune cells(TIIC)in high-grade tumors and pT2-pT4 tumors were higher than that in low-grade tumors and pTa-pT1 tumors(both P<0.05).At a cut-off of 10%,the expression levels of PD-L1 on TIIC in pT2-pT4 tumors were higher than that in pTa-pT1 tumors(P=0.014).The expression levels of PD-L2 on TC were not associated with the clinicopathological parameters such as histological grade and pT stage of UBC(all P>0.05).At a cut-off of 50%,the expression levels of PD-L2 on TIIC in pT2-pT4 tumors were higher than that in pTa-pT1 tumors(P=0.044).The expression status of PD-L1 and PD-L2 on TC did not correlate with the overall survival(OS)of UBC patients(all P>0.05).At a cut-off of 5%,patients with high PD-L1 expression on TIIC had shortened OS compared with those with low expression of PD-L1 on TIIC(P=0.011).The expression status of PD-L2 on TIIC did not correlate with the OS of UBC patients(P>0.05).Conclusion PD-L1 and PD-L2 are often abnormally expressed in UBC tumor cells and TIIC.Evaluating the expression status of PD-L1 and PD-L2 in UBC may provide the basis for immunotherapy.

关 键 词：膀胱肿瘤 尿路上皮癌 程序性死亡配体-1 程序性死亡配体-2 免疫组织化学 

分 类 号：R737.14[医药卫生—肿瘤]